A recombinant anti-CD38 fully human monoclonal antibody injection, HLX15 comes in both intravenous and subcutaneous ...
Dr. Reddy's Laboratories Ltd. closed 12.96% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...
Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...
Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...
HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...
An announcement from Dr Reddy’s Laboratories ( ($RDY) ) is now available. On February 4, 2025, Dr. Reddy’s Laboratories announced its ...
Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...
Dr Reddy’s Laboratories has signed a license deal with Shanghai Henlius Biotech to develop and market HLX15, an investigational cancer drug. Henlius will handle development and manufacturing, ...
Dr Reddy's Laboratories subsidiary signs licence agreement with Shanghai Henlius Biotech for development and ...
Dr Reddy’s Laboratories on Thursday said its subsidiary has inked a licence agreement with Shanghai Henlius Biotech, Inc to develop and commercialise an under-development cancer drug. Dr Reddy’s ...
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.68% to 1,227.95 Indian rupees Wednesday, on what proved to be an ...